Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma
The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).